Bain-Capital-backed Centrient Pharmaceuticals completed the acquisition of Astral SteriTech.

Bain-Capital-backed Centrient Pharmaceuticals, a manufacturer of beta-lactam antibiotics, completed the acquisition of Astral SteriTech, an international contract manufacturer specialized in sterile antibiotic powder injectable finished dosage forms. Financial terms were not disclosed. "The acquisition of Astral SteriTech is a significant step forward on the journey we at Centrient have undertaken to become the preferred commercial partner to our customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin antibiotics," Rex Clements, Centrient CEO.